Canada Pension Plan Investment Board Has $146.34 Million Stock Position in Pfizer Inc. $PFE

Key Points

• The Canada Pension Plan Investment Board reduced its stake in Pfizer Inc. by 30.1%, selling 2,484,464 shares and retaining approximately 5,775,134 shares of the biopharmaceutical company.
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding estimates, while the company's revenue grew by 10.3% year-over-year to $14.65 billion.
• Pfizer declared a quarterly dividend of $0.43 per share, representing an annualized payout of $1.72 with a dividend yield of 7.0%.

Canada Pension Plan Investment Board lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 30.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,775,134 shares of the biopharmaceutical company's stock after selling 2,484,464 shares during the quarter. Canada Pension Plan Investment Board owned 0.10% of Pfizer worth $146,342,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new stake in Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC lifted its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter worth approximately $27,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth approximately $28,000. Finally, North Capital Inc. purchased a new stake in Pfizer during the 1st quarter worth approximately $28,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

PFE traded up $0.14 during midday trading on Friday, reaching $24.74. The company's stock had a trading volume of 37,002,549 shares, compared to its average volume of 42,996,172. The company has a fifty day simple moving average of $24.79 and a 200 day simple moving average of $24.37. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The stock has a market cap of $140.65 billion, a P/E ratio of 13.16, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's payout ratio is presently 91.49%.

Analyst Ratings Changes

Several equities research analysts have issued reports on PFE shares. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. HSBC reduced their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Jefferies Financial Group boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.